作者
William Martin-Doyle, Jeffrey J Leow, Anna Orsola, Steven L Chang, Joaquim Bellmunt
发表日期
2015/2/20
来源
Journal of Clinical Oncology
卷号
33
期号
6
页码范围
643-650
出版商
American Society of Clinical Oncology
简介
Purpose
High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non–muscle-invasive bladder cancer, with highly variable prognosis, poorly understood risk factors, and considerable debate about the role of early cystectomy. We aimed to address these questions through a meta-analysis of outcomes and prognostic factors.
Methods
PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and American Society of Clinical Oncology abstracts were searched for cohort studies in HGT1. We pooled data on recurrence, progression, and cancer-specific survival from 73 studies.
Results
Five-year rates of recurrence, progression, and cancer-specific survival were 42% (95% CI, 39% to 45%), 21% (95% CI, 18% to 23%), and 87% (95% CI, 85% to 89%), respectively (56 studies, n = 15,215). In the prognostic factor meta-analysis (33 studies, n = 8,880), the highest impact risk factor was depth of …
引用总数
20142015201620172018201920202021202220232024112301426273139151914